oncology

Sutro Biopharma presented encouraging preclinical data for its ADC pipeline at AACR 2026, with lead candidate STRO-004 showing robust antitumor activity and plans for IND submissions in 2026.

Revolution Medicines reports promising Phase 1 data for zoldonrasib, showing 52% response rate in previously treated KRAS G12D lung cancer patients with manageable safety profile.

Boundless Bio presented preclinical data for BBI-940, an oral kinesin degrader targeting extrachromosomal DNA in breast cancer, with Phase 1 trials underway.

Revolution Medicines closes $2.2B concurrent offerings, including equity and convertible notes, to accelerate drug development and commercialization.

Zymeworks presents six ADC program updates at AACR 2026, including Phase 1 ZW191 clinical data and novel RAS-targeting platform preclinical results.

Revolution Medicines raises $2.0 billion via 10.56M shares at $142/share and $500M convertible notes for R&D and commercialization.

Tempus AI shares jumped 7.3% to $49.34 after 31 cancer research abstracts were accepted for AACR conference, though analyst coverage turns cautious.

Johnson & Johnson beat Q1 earnings expectations with 9.9% revenue growth driven by oncology products, but free cash flow plummeted 55.6% year-over-year.

Kazia in-licenses SETDB1 epigenetic platform from QIMR Berghofer to develop immunotherapy-resistant cancer treatment.

Iovance's Amtagvi cancer therapy targets $1B+ revenue by 2030 amid strong early growth, but faces manufacturing cost and regulatory risks.

Oxford BioTherapeutics partners with Bristol Myers Squibb to develop T-cell engager therapies for solid tumors, marking third major pharma deal in a year.

Zymeworks names permanent R&D and business development leaders, strengthening governance and strategic execution as it advances its clinical pipeline and asset aggregation strategy.

HUTCHMED to present preclinical data on first-in-class PI3K/PIKK therapy and updated Phase Ib/II surufatinib combination trial results at AACR Annual Meeting 2026.

Radiopharm Theranostics advances RAD202 radiopharmaceutical trial to higher dose cohort following positive safety review, remaining on track for 2026 Phase 1 completion.

Gilead acquires Tubulis for $3.15 billion including milestones, adding HER2-targeting ovarian cancer candidate to oncology pipeline—second major deal in months.

Telix Pharma reports 11% Q1 revenue growth to US$230M, reaffirms FY guidance, while advancing prostate and brain cancer pipelines through Phase 3 and regulatory milestones.

ORIC Pharmaceuticals granted 80,000 options and 15,000 RSUs to new hire under Nasdaq Rule 5635(c)(4), reflecting ongoing biotech talent competition.

Global molecular diagnostics market projected to grow from $18.26B in 2025 to $43.50B by 2035, driven by early disease detection demand and advanced technology adoption.

Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.

Merit Medical Systems acquires View Point Medical for $140M, adding breast cancer imaging technology. Expected to dilute 2026 earnings but turn accretive in 2027.